Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersActive in the last 2 years

Alette H. Ruarus

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0823-6398; OpenAlex author ID A5051795853. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 10

  1. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Co-author DOI 10.1136/jitc-2024-010222↗
  2. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… Co-author DOI 10.1016/s2468-1253(24)00017-7↗
  3. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival. Co-author DOI 10.1016/j.jvir.2023.06.027↗
  4. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Meta… Co-author DOI 10.3390/cancers13153902↗
  5. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. Co-author DOI 10.1016/j.jvir.2020.02.024↗
  6. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1016/j.tvir.2020.100675↗
  7. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  8. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activati… Co-author DOI 10.1080/2162402x.2019.1652532↗
  9. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? First author DOI 10.21037/cco.2019.10.05↗
  10. Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Co-author DOI 10.3390/cancers10010016↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hester J. Scheffer · 10 shared papers, 2018–2025 · strength 1.23
  2. Martijn Ruben Meijerink · 10 shared papers, 2018–2025 · strength 1.23
  3. Bart Geboers · 8 shared papers, 2019–2025 · strength 1.03
  4. Tanja D. de Gruijl · 7 shared papers, 2019–2025 · strength 0.92
  5. Laurien G. P. H. Vroomen · 6 shared papers, 2018–2025 · strength 0.76
  6. Florentine E. F. Timmer · 5 shared papers, 2020–2025 · strength 0.74
  7. Anna M E Bruynzeel · 2 shared papers, 2024–2025 · strength 0.37
  8. Frank J. Lagerwaard · 2 shared papers, 2024–2025 · strength 0.37
  9. Geert Kazemier M · 3 shared papers, 2019–2020 · strength 0.28
  10. Johanna W. Wilmink · 2 shared papers, 2020–2021 · strength 0.20
  11. Krijn P. van Lienden · 2 shared papers, 2020 · strength 0.19
  12. Eran van Veldhuisen · 2 shared papers, 2020 · strength 0.19
  13. Marc G. Besselink · 2 shared papers, 2020 · strength 0.19
  14. Babs M. Zonderhuis · 1 shared paper, 2020 · strength 0.10
  15. Jantien A. Vogel · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.